Simon Mark 4
4 · Cabaletta Bio, Inc. · Filed Oct 30, 2019
Insider Transaction Report
Form 4
Simon Mark
Director
Transactions
- Conversion
Common Stock
2019-10-29+18,144→ 18,144 total - Conversion
Series A-1 Preferred Stock
2019-10-29−27,217→ 0 total→ Common Stock (18,144 underlying)
Footnotes (1)
- [F1]Upon the closing of the Issuer's initial public offering, all shares of Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-1.5 basis. The Series A-1 Preferred Stock had no expiration date.